Perivascular epithelioid cell tumors (PEComa) – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030

Perivascular epithelioid cell tumors (PEComa) are a family of rare mesenchymal tumors composed of histologically and immunohistochemically distinctive perivascular epithelioid cells. These tumors include renal angiomyolipoma, lymphangioleiomyomatosis; clear cell sugar tumor of the lung; and similar tumors occurring in the retroperitoneum, kidney, uterus, pancreas, and a variety of other visceral and soft-tissue sites. PEComas of the kidney include various histologic subtypes of angiomyolipomas such as the classic angiomyolipoma, epithelioid angiomyolipoma, oncocytomalike angiomyolipoma, and lymphangiomyomatosis of the renal sinus. PEComas are related to the tuberous sclerosis complex (TSC) and have the characteristic genetic alterations of TSC, including the deletions of the short arm of chromosome 16p (TSC2 gene). Their perivascular location histologically characterizes PEComas, usually epithelioid or occasionally spindle cell morphology, and coexpression of human melanoma black (HMB)-45 and smooth-muscle markers.

 

PEComas-NOS arises at various visceral and soft tissue sites. Perivascular epithelioid cell tumors of the gastrointestinal tract (GI PEComas-NOS) comprise about 20% to 25% of PEComas-NOS. The overall incidence of Perivascular epithelioid cell tumors (PEComa) in the USA is 0.5 to 1.3 per million population.

 

 

The competitive landscape of Perivascular epithelioid cell tumors (PEComa) includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Perivascular epithelioid cell tumors (PEComa) across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Perivascular epithelioid cell tumors (PEComa) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Perivascular epithelioid cell tumors (PEComa) – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2020 To 2030

S. No    Asset               Company                                 Stage

1          ABI-009            Aadi, LLC          Phase 2

 

Comments

Post a Comment

Popular posts from this blog

Retinitis Pigmentosa (RP) – Market Access and Reimbursement Insights Report – 2025

Retinitis Pigmentosa (RP) Market Access and Reimbursement Insights Thelansis’s “Retinitis Pigmentosa (RP) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Key business questions answered: Market access and reimbursement for current therapies Coverage on plans Market access restrictions Rebates and contracting Factors influencing formulary access HEOR requirements and influence, etc. Expected market access and reimbursement for key emerging therapies Level of awareness Anticipated coverage on plans Factors that would improve mar...
Read more

Motor Neurone Disease (MND) – Market Access and Reimbursement Insights Report – 2025

Motor Neurone Disease (MND) Market Access and Reimbursement Insights Thelansis’s “Motor Neurone Disease (MND) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Motor Neurone Disease (MND) Overview Motor neurone disease is a progressive neurological condition in which the nerve cells that control voluntary muscle movement gradually deteriorate. As these neurons are lost, muscles weaken and shrink, leading to increasing difficulty with walking, speaking, swallowing, and eventually breathing. The disease usually begins subtly but advances relentlessly, with most patients facing a shortened life expectancy of only a few ye...
Read more

Uncomplicated Gonorrhea – Market Outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2024 To 2034

  Uncomplicated Gonorrhea Market Outlook Thelansis’s “Uncomplicated Gonorrhea Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Uncomplicated Gonorrhea treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Uncomplicated Gonorrhea Overview Uncomplicated gonorrhea is a common sexually transmitted infection (STI) caused by Neisseria gonorrhoeae, a bacterium that primarily affects the mucous membranes of the genital, rectal, and throat areas. The infection spreads through unprotected sexual contact and often presents mild or no symptoms, making early detection challenging. When symptoms do appear, they generally include a burning sensation...
Read more